{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Hemispherx BioPharma, Inc."},"Symbol":{"label":"Symbol","value":"AIM"},"Address":{"label":"Address","value":"2117 SW HIGHWAY 484, OCALA, Florida, 34473, United States"},"Phone":{"label":"Phone","value":"+1 352 448-7797"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19."},"CompanyUrl":{"label":"Company Url","value":"https://www.aimimmuno.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher McAleer","title":"Chief Scientific Officer"},{"name":"David R. Strayer","title":"Chief Medical Officer"},{"name":"Peter W. Rodino","title":"COO, Secretary & General Counsel"},{"name":"Thomas Kenwood Equels","title":"Executive Vice Chairman, President & CEO"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}